Management of type 2 diabetes: consensus of diabetes organizations

Article Details

Elaena Quattrocchi BS, PharmD, FASHP, CDE, Tamara Goldberg BS, PharmD, BCPS, Nino Marzella BS, MS, PharmD

Article Type


Related Articles

Article Page


Despite the advances in diabetes management, people with diabetes are not reaching their target glycemic goals. Healthcare professionals often fail to initiate, escalate, or de-intensify therapy when indicated. There are several organizations that provide guidance on the management of diabetes to assist the practitioner in achieving improved glycemic control, and this can cause confusion to the practitioner on which organizations’ guidance to follow. Diabetes mellitus is associated with an elevated risk of cardiovascular disease, and there have been studies that suggest some antidiabetic medications increase cardiovascular risk and some reduce cardiovascular risk. Diabetes organizations recommend the individualization of treatment goals and choices of drug therapy that will be safe and effective. Healthcare professionals should be knowledgeable and equipped to decide on the best treatment regimen for each of their patients with type 2 diabetes (T2D) and be familiar with how to utilize the different organizations’ philosophies in treating their patients.

Keywords: cardiovascular outcomes, consensus, diagnostic criteria, management of type 2 diabetes, renal outcomes, treatment goals, type 2 diabetes.

Citation: Quattrocchi E, Goldberg T, Marzella N. Management of type 2 diabetes: consensus of diabetes organizations. Drugs in Context 2020; 9: 212607. DOI: 10.7573/dic.212607

Contributions: All authors contributed equally to the preparation of this review. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at

Acknowledgments: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2020 Quattrocchi E, Goldberg T, Marzella N. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2020 Quattrocchi E, Goldberg T, Marzella N. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL:

Correspondence: Elaena Quattrocchi, BS, PharmD, FASHP, CDE, Associate Professor, Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Pharmacy, USA.

Provenance: invited; externally peer reviewed.

Submitted: 11 July 2019; Peer review comments to author: 2 September 2019; Revised manuscript received: 23 October 2019; Accepted: 27 November 2019; Publication date: 27 January 2020.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submission enquiries, contact the Editor-in-Chief

For all permissions, rights, and reprints, contact David Hughes

Download free full text PDF